News & Updates
Filter by Specialty:
SC vs IV pembrolizumab: Which route is better for metastatic NSCLC?
In patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), subcutaneous (SC) pembrolizumab (pembro) demonstrates comparable efficacy to that of intravenous (IV) pembro as regards overall exposure and trough concentration, reports a study presented at ELCC 2025.
SC vs IV pembrolizumab: Which route is better for metastatic NSCLC?
30 Apr 2025
Neoadjuvant chemo plus durvalumab improves survival in NSCLC
The addition of durvalumab to neoadjuvant chemotherapy with cisplatin and docetaxel results in better survival rates among patients with resectable nonsmall cell lung cancer (NSCLC), according to a study presented at ELCC 2025.
Neoadjuvant chemo plus durvalumab improves survival in NSCLC
30 Apr 2025
SOF/VEL combo improves well-being of children with CHC
In children with chronic hepatitis C (CHC), effective treatment with sofosbuvir/velpatasvir (SOF/VEL) results in improvements in certain areas of their well-being at 1 year. This suggests some patient-reported outcomes (PRO) benefits of direct-acting antiviral (DAA) therapy. However, the parents’ proxy reports show a decrease in the patients’ school functioning.
